Membrane Transporters as Key Players in Calcium and Phosphate Homeostasis

by

Introduction

Calcium and phosphate are macrominerals that have major functions in the body processes as well as for the formation of bones, metabolism, and cell functionality. More importantly, homeostasis of these minerals is ensured for the efficient functioning of biological systems in the body. Calcium plays a significant role in muscle contraction and neural transmission, blood clotting, and phosphate participates in common metabolic pathways involving energy generation and nucleic acid formation. The many minerals are actively transported across the cell membranes by specific membrane carriers, which maintain the concentrations of these minerals in different tissues. Abnormality in these transporters causes multiple diseases, for instance, osteoporosis, hypercalcemia, and kidney diseases, among them. Membrane transporters and their role in cation and anion regulation/calcium phosphate balance: implications in health and disease are discussed here.

The Importance of Calcium and Phosphate in Biological Systems

Calcium and phosphate complement each other in the body and particularly in bone formation because calcium phosphate is the structural foundation of hydroxyapatite, the mineral part of bones. Calcium ions are also known to play an important role in cellular signaling processes such as muscle contraction and neurotransmission. Phosphate, on the other hand, is part of ATP, which is the energy coin of any cell and is involved in the regulation of a myriad of enzymes and proteins. Annually, the body of a healthy person receives 1000–1500 mg of calcium daily and retains only a part of it in its system since calcium, like phosphate, is filtered through the kidneys and it also needs to be tightly regulated and controlled with phosphate ions inside cells and out of cells.

The Role of Calcium Channels and Transporters in Homeostasis

Calcium balance is controlled primarily by hormonal balance (including parathyroid hormone and calcitriol) as well as by carriers. These transporters are required for intestinal absorption, renal reabsorption, and bone storage of calcium.

After investigation, it was identified that TRPV5, a calcium-selective phosphate ion channel that operates in the kidneys, is one of the crucial transporters of calcium. It seems that TRPV5 is involved in the absorption of calcium from the urine into the bloodstream to avoid the depletion of this ion. Research has established that the TRPV5 channel is crucial for the management of calcium homeostasis and that malfunction or absence of the TRPV5 protein results in hypercalciuria and may also cause osteopenia.

TRPV6 is another member of the transient receptor potential vanilloid family, which is involved in intestinal calcium absorption. Even though TRPV6 is related to TRPV5 in homologous terms, the primary requirement function is essential for proper and efficient absorption of calcium in the diet. It is observed that TRPV6 deficiency causes Площадь and other negative impacts on anatomical calcium convenience and thus systemic calcium balance.

Besides TRPV5 and TRPV6, plasma membrane calcium ATPases (PMCA) are important as calcium pumps to transport the extra calcium out of cells to control intracellular calcium levels. PMCA is expressed in cells that need calcium homeostasis for their function—neurons and muscle cells. PMCA malfunction leads to neurodegenerative illnesses or muscle dystrophy.

Yearwise Publication Trend on “homeostasis”

Find publication trends on relevant topics

Phosphate Transporters: Guardians of Phosphate Homeostasis

Similar to calcium, the regulation of phosphate is very specific and maintained by specific transport proteins to check the relative phosphate levels in the different tissues. Transmembrane protein SLC34A1 in the kidneys, which is referred to as the sodium-phosphate cotransporter IIa (NaPi-IIa), has extensive play in phosphate reabsorption. The phosphate is reabsorbed through this transporter to ensure that an abundance of phosphate is not expelled through the urine. Defects in the SLC34A1 protein are linked with diseases such as hereditary hypophosphatemic rickets, in which high loss of phosphate to urine results in softening of bones and deformity.

Another group involving phosphate balance is the SLC20 family, including PiT1 and PiT2 transporters. This receptor is involved in phosphate transport in different organs, with special emphasis on bones and the liver. Special attention should be given to paiPiT1, which is necessary for bone growth, as it has been found out that its defect leads to impaired mineralization of bones. Likewise, we know PiT2 to be vital for the cellular transport of phosphate; mutations of this gene can prevent normal bone remodeling and give rise to metabolic diseases.

Calcium-Phosphate Interactions and the Role of SLC34A1

Two of the most intriguing properties of calcium and phosphate metabolism involve how they are interrelated, particularly the bone tissue. Calcium and phosphate work hand in hand to form hydroxyapatite crystals to give bone the requisite strength. The SLC34A1 transporter regulates the concentration of calcium and phosphate in the kidneys as a focus of balance. Therefore, through the recycling of phosphate and its influence over calcium levels to some extent, the SLC34A1 device for maintaining BMD.

Where SLC34A1 function is impaired, for example by a genetic condition, phosphate is excreted in urine to cause hypophosphatemic diseases such as rickets or osteomalacia, which is characterized by weak bone structure. A shortage of enough phosphate compromises the fosfor/calcium ratio, thus leading to undesirable bone deposition.

The Role of Ion Channels in Bone Resorption and Formation

Bone mass is the result of the activity of osteoblasts, the bone-forming cells, and osteoclasts, the bone-destroying cells. Ion channels are instrumental in osteoclast-induced bone resorption, in which calcium and phosphate are mobilized from the bone stores into the bloodstream. ClC-7, a chloride-proton antiporter, is required to maintain the acidic environment of osteoclasts to dissolve bone minerals. An impairment of ClC-7 function leads to a disease known as osteopetrosis, which can be described as a condition in which bones are too dense and their resorption is difficult.

The other important regulator of bone resorption is the vacuolar-type H+-ATPase (V-ATPase), which ionizes resorption lacuna in such a way that osteoclasts disintegrate bone minerals and release Ca and P. V-ATPase plays a central role in bone remodeling owing to its link to diseases such as osteopetrosis.

Recent Publications on “homeostasis”

Find publications on relevant topics

The Pathological Consequences of Dysregulated Calcium and Phosphate Homeostasis

The diseases caused by negative allosteric regulation of proteins involved in the transport of calcium and phosphate are severe. Other diseases include diseases of bones, namely osteoporosis, osteopenia, osteopetrosis, hypercalcemia, hypocalcemia, and diseases due to dysregulation of calcium transporters that are potentially dangerous to the whole body. Hypercalcemia, a high calcium level in the blood, can cause kidney stones, heart disease, and other issues in the nervous system. In contrast, hypocalcemia or low blood calcium levels may lead to a spasm, seizure, or altered cardiac rhythm.

Likewise, any disturbances with phosphate homeostasis may result in diseases of various kinds, including the possibility of cancer, according to the author. For instance, hypophosphatemia associated with mutations in phosphate transporters such as sodium phosphate cotransporter 2a (SLC34A1) can lead to low bone mineral density and strength, fractures, and muscle weakness. Hyperphosphatemia, which is a condition of raised phosphate, is often observed in CKD and is a direct precursor to vascular calcification, which shrinks blood vessels, increasing cardiovascular morbidity in CKD patients.

Emerging Therapeutic Targets

Because calcium and phosphate play critical roles in physiology and disease, membrane transporters are now appealing targets for drugs for diseases associated with these ions. For example, blockade of osteoclast activity to target V-ATPase or ClC-7 may yield novel therapies for osteoporosis as well as other bone-invading diseases. Likewise, regulation of TRPV5 and TRPV6 can bring some relief and cure diseases, including hypercalciuria and kidney stones.

Thus, there is a possibility of developing inhibitors of SLC34A1 or SLC20 transporters for the treatment of various diseases, such as hyperphosphatemia or phosphate-wasting diseases. While more information is discovered about them at the molecular level, new drugs that target calcium and phosphate transport may provide light for people with metabolic and bone disorders.

Conclusion

Depending on the function, membrane transporters are fundamental clinically for calcium and phosphate homeostasis and affect bone health, cell processes, and energy generation. Abnormalities in these transporters potentially contribute to a variety of diseases, including osteoporosis and metabolic diseases. As more information about these transporters is discovered, novel approaches to control their activity and consequently the disorders related to calcium and phosphate metabolism are expected to be developed.

References

  1. Hughes, T.E., Del Rosario, J.S., Kapoor, A., Yazici, A.T., Yudin, Y., Fluck III, E.C., Filizola, M., Rohacs, T. and Moiseenkova-Bell, V.Y., 2019. Structure-based characterization of novel TRPV5 inhibitors. Elife, 8, p.e49572.
  2. Schumann, T., König, J., Henke, C., Willmes, D.M., Bornstein, S.R., Jordan, J., Fromm, M.F. and Birkenfeld, A.L., 2020. Solute carrier transporters as potential targets for the treatment of metabolic disease. Pharmacological reviews, 72(1), pp.343-379.
  3. Liu, S., Chang, S., Han, B., Xu, L., Zhang, M., Zhao, C., Yang, W., Wang, F., Li, J., Delpire, E. and Ye, S., 2019. Cryo-EM structures of the human cation-chloride cotransporter KCC1. Science, 366(6464), pp.505-508.
  4. Sims, N.A. and Martin, T.J., 2020. Osteoclasts provide coupling signals to osteoblast lineage cells through multiple mechanisms. Annual review of physiology, 82(1), pp.507-529.
  5. Schrecker, M., Korobenko, J. and Hite, R.K., 2020. Cryo-EM structure of the lysosomal chloride-proton exchanger CLC-7 in complex with OSTM1. Elife, 9, p.e59555.
  6. Cao, B., Dai, X. and Wang, W., 2019. Knockdown of TRPV4 suppresses osteoclast differentiation and osteoporosis by inhibiting autophagy through Ca2+–calcineurin–NFATc1 pathway. Journal of cellular physiology, 234(5), pp.6831-6841.
  7. Futai, M., Sun-Wada, G.H., Wada, Y., Matsumoto, N. and Nakanishi-Matsui, M., 2019. Vacuolar-type ATPase: A proton pump to lysosomal trafficking. Proceedings of the Japan Academy, Series B, 95(6), pp.261-277.

Top Experts on “homeostasis“